⚠️Hazardous Drug Definition & Occupational Risk
NIOSH Hazardous Drug List: Chemotherapy agents appear on the NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings. These drugs require special handling due to their intrinsic toxicity profile.
Why Chemotherapy is an Occupational Hazard
Chemotherapy drugs are classified as occupational hazards because they are:
- Mutagenic — capable of causing DNA mutations in healthy cells
- Teratogenic — harmful to developing foetuses; risk to pregnant nurses
- Carcinogenic — long-term occupational exposure linked to increased cancer risk
Routes of Nurse Exposure
Skin Contact
Most common route. Glove breaches, surface contamination, spills during priming
Inhalation
Aerosol generation during preparation, spills, or open-system transfers
Ingestion
Hand-to-mouth contact; not eating/drinking where chemo is handled is critical
🔒Closed System Drug Transfer Devices (CSTDs)
Mandatory in GCC JCI-accredited hospitals: CSTDs mechanically prohibit the transfer of environmental contaminants into the system and the escape of hazardous drug vapour or liquid outside the system.
Approved CSTD Systems in Use
Texium
BD Texium — needle-free closed male luer
PhaSeal
Carmel Pharma — widely used in GCC oncology units
ICU Medical
Clave / ChemoClave series for IV drug transfer
🦺Personal Protective Equipment (PPE) for Administration
| PPE Item | Specification | Notes |
|---|
| Gloves | Double nitrile — ASTM D6978 tested | Change inner glove every 30 min; never latex (allergy risk) |
| Gown | Impermeable, low-lint, long-sleeve, closed-front | Single-use; discard after each patient/spill |
| Face Shield / Goggles | Full face shield if spill risk; goggles minimum | Mandatory during priming; vesicant administration |
| Respirator | N95 or higher if spill or aerosol risk | Standard surgical mask NOT sufficient for chemo vapour |
🤰Pregnant Nurses & Chemotherapy
GCC Hospital Policy: Pregnant nurses should NOT prepare or administer chemotherapy. This is supported by NIOSH, ONS, and most GCC hospital policies, though enforcement varies between institutions.
- Risk exists throughout all trimesters — first trimester particularly critical for organogenesis
- Declare pregnancy to your line manager early — document your request for redeployment in writing
- If redeployment is refused, escalate to occupational health/HR and know your rights under local labour law
- GCC nationals may have stronger protections; expatriate nurses should review employment contracts
- Advocate for yourself — do not silently accept unsafe assignments
🧪Biological Safety Cabinet & Preparation
- Class II Type B2 BSC (Laminar Flow Hood) — required for preparing all hazardous drugs
- Pharmacy-prepared chemotherapy is the gold standard — nurses should receive ready-to-administer bags where possible
- Nurses should NOT reconstitute or mix chemotherapy outside a certified BSC
- BSC must be certified every 6 months; decontaminated before and after use
- Dedicated chemotherapy preparation area — negative pressure room preferred
✅Two-Nurse Independent Verification Process
Requirement: Two chemotherapy-trained nurses must independently verify the order before administration. Both nurses must physically check each parameter — not simply countersign.
Verification Checklist
🩸Blood Count Criteria Before Administration
Neutrophils (ANC)
Safe threshold: ANC >1.0–1.5 × 10⁹/L
Protocol-specific — always refer to the treatment protocol. Some regimens allow ANC >1.0; others require >1.5.
- ANC 1.0–1.5: proceed with caution per protocol
- ANC 0.5–1.0: typically hold — discuss with oncologist
- ANC <0.5: severe neutropenia — do NOT administer without explicit oncologist override
Platelets
Safe threshold: Platelets >75,000–100,000 /µL
Protocol-specific. Some agents (e.g. carboplatin) have lower thresholds per protocol.
- Platelets <50K: most protocols hold chemotherapy
- Document all blood result times and who authorised administration
- If patient had G-CSF, note last injection time — can falsely elevate counts
🫘Renal Function & Dose Adjustment
Critical: Renally-cleared chemotherapy requires CrCl calculation before every cycle. Never assume stable renal function between cycles.
Creatinine Clearance Calculation Methods
| Formula | Use Case | Notes |
|---|
| Cockcroft-Gault | Standard oncology practice | Use actual body weight (or IBW if obese) |
| CKD-EPI | More accurate in borderline renal impairment | Increasingly used for carboplatin AUC dosing |
| Calvert Formula | Carboplatin AUC dosing | Dose (mg) = AUC × (GFR + 25) |
Renally-Cleared Agents — Hold / Dose-Reduce Thresholds
| Drug | Consideration |
|---|
| Cisplatin | Hold if CrCl <60 mL/min; requires aggressive IV hydration (1–2L pre/post); nephrotoxic |
| Carboplatin | Dose calculated by AUC using CrCl — AUC 5–6 typical; dose falls with renal impairment |
| Methotrexate (high-dose) | Contraindicated if CrCl <50 mL/min; requires leucovorin rescue and urine alkalinisation |
| Bleomycin | Dose reduce if CrCl <40 mL/min; pulmonary toxicity risk increased |
🫀Liver Function & Cumulative Dose Limits
LFT-Based Dose Reduction
Hepatically-metabolised agents require LFT check before each cycle:
- Doxorubicin — reduce 50% if bilirubin 1.2–3.0; 75% if >3.0 mg/dL
- Vincristine/Vinorelbine — dose reduce with elevated bilirubin
- Irinotecan — increased toxicity with hepatic dysfunction; hold if elevated
- Docetaxel/Paclitaxel — dose reduce if AST/ALT >2.5× ULN or bilirubin elevated
Cumulative Dose Limits — Anthracyclines
Cardiotoxicity Risk: Cumulative anthracycline dose must be tracked across ALL cycles and lines of treatment.
| Drug | Lifetime Max |
|---|
| Doxorubicin | 450–550 mg/m² |
| Epirubicin | 900–1000 mg/m² |
| Daunorubicin | 400–600 mg/m² |
| Liposomal Dox. | ~550 mg/m² |
LVEF monitoring (ECHO/MUGA) required at baseline, and at cumulative doses of 300 mg/m² and 450 mg/m².
💉Vesicant / Irritant / Non-Vesicant Classification
| Classification | Definition | Extravasation Consequence |
|---|
| Vesicant | Causes tissue necrosis and blistering on extravasation | Severe tissue damage, ulceration, may require surgery |
| Irritant | Causes local inflammation and pain but not necrosis | Pain, erythema, phlebitis — usually resolves |
| Non-Vesicant | Minimal tissue damage on extravasation | Localised swelling/mild irritation |
🚨Critical Vesicant Agents
Anthracyclines
- Doxorubicin (Adriamycin)
- Epirubicin
- Daunorubicin
- Idarubicin
Vinca Alkaloids
- Vincristine
- Vinblastine
- Vinorelbine
Alkylating Agents
- Mechlorethamine (nitrogen mustard) — highly vesicant
- Carmustine (BCNU)
Taxanes
- Docetaxel — irritant-to-vesicant range
- Paclitaxel — irritant; vesicant at high concentrations
🔍Vesicant Administration Safety Protocol
Central line is strongly preferred for vesicant administration. Peripheral IV is acceptable only with a newly placed, confirmed-patent cannula.
- Assess IV site before starting — flush with 10mL NS, confirm no resistance, no swelling, no pain
- Central line preferred — PICC, Hickman, implanted port (Portacath)
- If peripheral: use antecubital fossa or forearm — AVOID dorsum of hand, wrist, and antecubital crease
- Assess every 2–5 minutes during infusion — do not leave the bedside during vesicant administration
- Patient instruction: immediately report any pain, burning, stinging, or swelling at the site
- Keep antidote medications physically available in the unit before starting
- Document site assessment in the nursing notes every 15 minutes
🆘Extravasation Emergency Protocol
Extravasation = STOP IMMEDIATELY. Time-sensitive — antidote must be given within hours for anthracyclines.
- STOP the infusion immediately — do not remove the cannula
- Aspirate as much residual drug as possible through the existing cannula (2–5 mL)
- Remove cannula after aspiration attempt
- Elevate the affected limb
- Photograph the site — document size, appearance, time
- Apply antidote per protocol (see table below)
- Notify oncologist and plastic surgery team
- Complete incident report / CIRS notification per hospital policy
Specific Antidotes
| Drug Class | Antidote | Instructions |
|---|
| Anthracyclines (doxorubicin, epirubicin) | Dexrazoxane (Totect/Savene) | IV infusion × 3 days; must start within 6 hrs. First dose 1000 mg/m², second 1000 mg/m² (Day 2), third 500 mg/m² (Day 3) |
| Vinca alkaloids | Hyaluronidase | 150–1500 units SC around the extravasation site; apply warm compress (NOT cold) |
| Mechlorethamine | Sodium thiosulfate 1/6 M | Inject SC around site; cold compress |
| Taxanes | Cold compress; hyaluronidase may be used | Apply dry cold pack; elevate limb |
☠️Intrathecal Vincristine — Never Event
NEVER NEVER NEVER administer vincristine intrathecally. This is invariably fatal.
Intrathecal vincristine causes ascending paralysis, seizures, and death. There is no antidote.
- WHO and all major oncology bodies classify this as a Never Event
- Vincristine for IV use should arrive from pharmacy in a 50 mL minibag — not a syringe — to prevent accidental intrathecal injection
- Intrathecal bags must be labelled: "FOR INTRATHECAL USE ONLY"
- Vincristine bags must be labelled: "FOR INTRAVENOUS USE ONLY — FATAL IF GIVEN INTRATHECALLY"
- If vincristine arrives as a syringe, do not administer — return to pharmacy
- Both the IV vincristine and any intrathecal chemotherapy (e.g. methotrexate, cytarabine) should be prepared and delivered at different times and in clearly differentiated packaging
🦠Haematological Toxicity — Myelosuppression
Nadir: Most cytotoxic regimens produce a blood count nadir at Day 7–14 post-administration. Patients must be educated to monitor for fever during this window.
Neutropenia Grading (CTCAE v5)
| Grade | ANC (×10⁹/L) | Action |
|---|
| Grade 1 | 1.5 – LLN | Monitor; proceed per protocol |
| Grade 2 | 1.0 – 1.5 | Caution; protocol-dependent hold |
| Grade 3 | 0.5 – 1.0 | Hold next cycle; G-CSF |
| Grade 4 | <0.5 | Severe; high infection risk |
Febrile Neutropenia — Emergency
Definition: Fever ≥38.3°C single reading OR ≥38°C sustained × 1hr, PLUS ANC <0.5 × 10⁹/L (or <1.0 × 10⁹/L expected to fall).
- IV antibiotics must be given within 1 hour of triage
- First-line: Piperacillin/Tazobactam 4.5g IV TDS (or as per hospital protocol)
- Add vancomycin if central line infection suspected
- Blood cultures ×2 (peripheral + CVC) before antibiotics if possible — do NOT delay antibiotics for cultures
G-CSF (Granulocyte Colony-Stimulating Factor) Prophylaxis
- Filgrastim / Pegfilgrastim — stimulate neutrophil production to reduce nadir severity
- Primary prophylaxis: regimens with >20% febrile neutropenia risk (e.g. CHOP, TAC, BEP)
- Give 24–72 hours after last chemotherapy dose — not within 24 hours before or after chemo
- Pegfilgrastim (Neulasta) — single dose per cycle preferred for compliance
- Document G-CSF administration — affects ANC interpretation at follow-up visit
🤢Chemotherapy-Induced Nausea & Vomiting (CINV)
CINV Classification
| Type | Timing | Mechanism |
|---|
| Acute | 0–24 hours after chemo | 5HT3 receptor activation in GI tract and CTZ |
| Delayed | 24–120 hours after chemo | Substance P / NK1 pathway dominant |
| Anticipatory | Before administration | Conditioned response — psychological; prior bad experience |
| Breakthrough | Despite prophylaxis | Requires rescue antiemetics |
| Refractory | Subsequent cycles | Adjust prophylaxis regimen |
Emetogenicity & Antiemetic Prophylaxis
Highly Emetogenic (HEC): Cisplatin, Cyclophosphamide ≥1500 mg/m², Dacarbazine, Mechlorethamine, Streptozocin
Recommended prophylaxis: NK1 antagonist (aprepitant/fosaprepitant) + 5HT3 antagonist (ondansetron/granisetron) + Dexamethasone ± Olanzapine 10mg
Moderately Emetogenic (MEC): Carboplatin, Cyclophosphamide <1500 mg/m², Doxorubicin, Irinotecan, Oxaliplatin
Recommended prophylaxis: 5HT3 antagonist + Dexamethasone ± NK1 antagonist (for AC/EC breast cancer — use triple therapy)
👄Mucositis — Grading & Management
| CTCAE Grade | Description | Management |
|---|
| Grade 1 | Asymptomatic — ulceration not visible; only erythema | Oral rinses; soft diet; oral hygiene protocol |
| Grade 2 | Moderate pain; oral intake modified; not limiting ADLs | Salt/soda mouthwash; magic mouthwash; analgesic rinses |
| Grade 3 | Severe pain; oral intake severely limited | IV fluids; parenteral analgesia; TPN consideration; antifungal/antiviral if indicated |
| Grade 4 | Life-threatening; urgent intervention required | ICU-level care; parenteral nutrition; IV opioids; specialist input |
Drugs most associated with mucositis: 5-Fluorouracil Methotrexate Capecitabine Doxorubicin Irinotecan
⚡Peripheral Neuropathy (CIPN) & Alopecia
Chemotherapy-Induced Peripheral Neuropathy
Most commonly caused by:
- Taxanes — paclitaxel, docetaxel (sensory > motor)
- Platinum agents — oxaliplatin (cold dysaesthesia acutely), cisplatin (cumulative)
- Vinca alkaloids — vincristine (motor + sensory)
- Bortezomib — painful neuropathy common
Symptoms: numbness, tingling, burning, loss of proprioception. Monitor with standardised tool (e.g. TNS or FACT/GOG-NTX). May require dose reduction or agent change.
Alopecia Counselling
Always counsel BEFORE the first cycle — hair loss typically begins 2–4 weeks after first administration.
- Temporary alopecia: most cytotoxic agents — hair regrows 3–6 months post-completion; texture and colour may change initially
- Permanent alopecia: rare — docetaxel (especially high cumulative dose and dose-dense schedules); busulfan conditioning
- Scalp cooling: increasingly available in GCC — may reduce alopecia risk for certain agents; not used with haematological malignancies or scalp mets
- Offer referral to wig service / support groups before hair loss starts
📋Chemotherapy Education Checklist
Check each item when patient education has been provided. Progress is saved automatically.
🚨EMERGENCY WARNING SIGNS — Teach-Back Required
Patient must be able to recite these independently. Use teach-back: "Can you tell me in your own words when you should go to the emergency department?"
GO TO ED IMMEDIATELY:
- Fever ≥38°C — even if feeling "okay" — febrile neutropenia is a medical emergency
- Severe or uncontrolled bleeding — nose, gums, blood in urine/stool
- Severe vomiting — more than 4×/day or unable to keep any fluids down
- Chest pain or shortness of breath — possible PE, cardiac toxicity
- Sudden severe headache — intracranial bleed if thrombocytopenic
- Signs of severe allergic reaction — hives, throat swelling, difficulty breathing
CALL YOUR ONCOLOGY TEAM (within 24hr):
- Diarrhoea >4 times/day or bloody stool
- Mouth sores making it difficult to eat or drink
- New pain, numbness, or tingling in hands/feet
- Significant swelling at IV or port site
- Unable to take oral chemotherapy or medications as prescribed
- Any new symptom that concerns you
🥗Neutropenic Diet & Food Safety (GCC Context)
Neutropenic diet is recommended when ANC <1.0 × 10⁹/L. Evidence is evolving — most centres now use a "food safety" approach rather than strict low-microbial diet.
Avoid During Neutropenia
- Raw or undercooked meat, poultry, seafood, eggs
- Unpasteurised dairy products (raw milk, some soft cheeses)
- Unwashed or pre-cut fresh fruit and vegetables
- Restaurant buffets and salad bars — GCC context: hotel/restaurant buffets particularly high risk
- Fresh salads at restaurants — unknown washing procedures
- Raw sprouts, deli meats, unpasteurised juices
Safe Food Practices
- Wash hands before preparing and eating food
- Cook all meat to safe internal temperatures
- Thoroughly wash all fresh produce
- Refrigerate leftovers within 2 hours; eat within 24 hours
- Avoid sharing food, cups, or utensils
- Home-cooked meals preferable during nadir period
GCC Note: Traditional communal meals (mandi, harees, large family platters) may be a concern during nadir. Advise patients to serve themselves from freshly-cooked portions and avoid reheated buffet-style service.
🦷Infection Prevention & Oral Hygiene
Hand Hygiene
- Wash hands with soap and water for 20 seconds before eating, after toilet, after touching surfaces in public
- Alcohol-based hand rub is acceptable and convenient
- Avoid shaking hands or close physical contact with visibly unwell people
- Avoid crowds and enclosed spaces during nadir
Oral Hygiene Protocol
- Soft-bristled toothbrush — replace every 1–3 months
- Brush gently twice daily; floss with care if platelets allow
- Use alcohol-free mouthwash — alcohol causes mucosal drying
- Sodium bicarbonate rinse (1 tsp in 250mL water) 4–6× daily is recommended
- Treat mucositis early — do not wait for Grade 3
- Avoid spicy, acidic, or rough-textured foods with mucositis
🩺PICC Line & Port Patient Education
PICC Line Care
- Keep dressing clean, dry, and intact — change weekly or if soiled/loosened
- Do not submerge arm in bath/swimming pool
- Do not take blood pressure on PICC arm
- Flush with heparinised saline as per protocol (weekly if not in use)
- Report: redness, pain, swelling, dressing coming off, leaking, or arm swelling
Implanted Port (Portacath)
- Flush monthly if not in use (heparinised saline)
- Report any swelling, redness, pain over the port site
- Avoid pressure/trauma to port area
- Always use a non-coring (Huber) needle to access
- You can shower normally — port is under the skin
- Carry your port card — inform all healthcare providers of your port
🌍GCC Oncology Landscape
Rapid growth: GCC countries have significantly expanded oncology infrastructure in the last decade. Comprehensive cancer centres now offer full chemotherapy, immunotherapy, and bone marrow transplant services.
Major Cancer Centres in GCC
| Centre | Country | Services |
|---|
| National Centre for Cancer Care & Research (NCCCR) | Qatar | Full oncology; BMT; clinical trials |
| King Faisal Specialist Hospital & Research Centre (KFSHRC) | Saudi Arabia (Riyadh) | Comprehensive cancer; BMT; proton therapy |
| Cleveland Clinic Abu Dhabi | UAE (Abu Dhabi) | Oncology; haematology; comprehensive cancer care |
| Tawam Hospital | UAE (Al Ain) | Johns Hopkins-affiliated; oncology referral centre |
| American Hospital Dubai | UAE (Dubai) | Full oncology; JCI-accredited; chemotherapy |
| King Abdulaziz Medical City (NGHA) | Saudi Arabia | Network of oncology units across KSA |
👩⚕️Chemotherapy Nurse Workforce in GCC
Shortage: Demand for oncology-trained nurses is growing faster than the supply across all GCC countries. This has direct patient safety implications.
Recruitment Patterns
- GCC hospitals actively recruit chemotherapy-trained nurses from the Philippines, India, UK, and Australia
- Philippines: large volume of oncology-trained nurses; ONS certification increasingly common
- UK nurses bring experience with SACT (Systemic Anti-Cancer Treatment) protocols
- Two-year minimum oncology experience typically required for senior chemo nurse roles
Certifications Valued in GCC
- ONS Chemotherapy Biotherapy Certificate — Oncology Nursing Society; widely recognised and valued by GCC oncology units
- BMTCN — Blood & Marrow Transplant Certified Nurse (for BMT units)
- OCN — Oncology Certified Nurse (ONS board certification)
- BLS/ACLS — Mandatory for all oncology nurses in GCC
ONS Chemo Biotherapy cert is a key differentiator for GCC oncology nursing job applications.
🕌Islamic & Cultural Considerations
Halal Status of Antiemetics
Oral ondansetron (Zofran) and some other oral antiemetics may contain porcine gelatine in the capsule coating.
IV ondansetron is gelatin-free and acceptable.
For oral preparations, check the manufacturer package insert or substitute with a halal-certified formulation where available.
- Most Muslim scholars permit gelatin-containing medications when no halal alternative exists (principle of necessity — darura)
- However, where a halal alternative exists and is equally effective, it should be used
- Always check with pharmacy when in doubt; document patient preference
Ramadan & Chemotherapy
Timing: Where clinically safe and the patient's condition allows, consider timing chemotherapy cycles to avoid Ramadan fasting days — particularly for highly emetogenic regimens.
- IV medications and infusions are generally permissible during Ramadan fasting according to Islamic scholarly consensus — they do not break the fast
- IV antiemetics and IV fluids are therefore acceptable during fasting hours
- Hydration challenge: Cisplatin requires significant IV hydration — this must be planned carefully during Ramadan; most patients will require hospital-based hydration
- Oral medication timing: adjust to suhoor (pre-dawn meal) or iftar (breaking fast)
- Discuss fasting plans openly with the patient — involve the patient's imam or Islamic scholar if requested
💊Oral Chemotherapy — GCC Considerations
Oral chemotherapy agents are as hazardous as IV chemotherapy. Patients and families must understand this.
Common Oral Chemotherapy Agents
- Capecitabine (Xeloda) — colorectal, breast; twice daily with food; hand-foot syndrome
- Temozolomide (Temodar) — brain tumours (GBM); taken fasting; nausea common
- Imatinib/Gleevec — CML; daily; requires adherence monitoring
- Erlotinib/Gefitinib — NSCLC EGFR-mutated; daily
- Abiraterone + prednisone — prostate cancer; requires steroid co-administration
GCC Follow-Up Challenges
- Patients may travel between GCC countries and home countries — continuity of monitoring is critical
- Family proxy collection of medications is common — patient may not be administering correctly
- Some patients share medications between family members with "similar" diagnoses — educate firmly against this
- Document patient's understanding at every visit; use teach-back
- WhatsApp patient education and medication reminders are increasingly used and culturally accepted in GCC
🤝Cultural Aspects of Cancer Diagnosis Disclosure
Ethical tension in GCC: In Arab and South Asian cultures, family members may request that the patient NOT be told their cancer diagnosis. This creates a direct conflict with Western bioethical principles of patient autonomy.
Family-First Culture
- It is common for family members to speak to the physician before the patient and request non-disclosure
- The family may believe they are protecting the patient from psychological harm
- In some GCC hospitals, family consent is given significant weight — practice varies
- Nurses frequently navigate this tension daily in oncology units
Nursing Considerations
- Know your hospital's disclosure policy and the local legal framework
- Support the patient's right to know — gently and consistently
- If a patient directly asks "Do I have cancer?" — you cannot lie; document the conversation
- Involve the oncologist, palliative care team, and social worker in complex cases
- Provide privacy — give patients opportunity to ask questions without family present
- Cultural competence does not mean compromising patient autonomy